Bosatria (GSK) study in severe Eosinophilic Asthma

A year-long study involving 621 patients treated with Bosatria (mepolizumab) from Glaxo Smith Kline found that the rate in patients on mepolizumab of clinically significant exacerbations - defined as episodes requiring oral corticosteroids or a hospital visit - was around half that of those on placebo. But while monthly intravenous injections of the drug cut attacks they failed to produce consistent improvements in symptoms or lung function, suggesting that this aspect of the illness might require different treatment.